Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2024-12-18 DOI:10.1002/cam4.70272

Sarah Waliany, Misako Nagasaka, Leah Park, Clara Lam, Zoe Jiang, Feng Lin, Joel W. Neal

{"title":"Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database","authors":"Sarah Waliany, Misako Nagasaka, Leah Park, Clara Lam, Zoe Jiang, Feng Lin, Joel W. Neal","doi":"10.1002/cam4.70272","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Targeted therapies have been shown to improve outcomes in metastatic non-small cell lung cancer (mNSCLC) with driver mutations. We evaluated the real-world prevalence of human epidermal growth factor receptor 2 (HER2; <i>ERBB2</i>) tumor gene mutations among patients with mNSCLC and described historical treatments and outcomes in patients with <i>HER2</i>-mutant mNSCLC, during a period when there was no approved targeted therapy for <i>HER2</i>-mutant mNSCLC.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>This retrospective observational study used a US nationwide de-identified NSCLC clinico-genomic database. Eligible patients were adults diagnosed with <i>HER2</i>-mutant mNSCLC from January 2014 to July 2021 without co-occuring epidermal growth factor receptor (<i>EGFR</i>) tumor mutations. Descriptive statistics were used to summarize prevalence, baseline characteristics and treatment patterns. Clinical outcomes were estimated with Kaplan–Meier analyses.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 9206 patients with mNSCLC, 164 (1.78%) met the eligibility criteria (mean age: 67.3 years, 63.4% White, 56.7% female, and 53.0% with a smoking history). 132/164 (80.5%) had at least one line of treatment. Platinum-based chemotherapy (45.5%) and immune checkpoint inhibitor (ICI) with chemotherapy (28.0%) were the most frequently used first-line treatments. The median (95% confidence interval [CI]) real-world (rw) progression-free survival in first-line was 5.5 (4.8, 6.2) months and 3.0 (2.3, 4.2) months in second-line. The median rw overall survival in first-line was 13.2 (10.6, 18.4) months and 8.2 (6.6, 13.2) months in second-line.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>During this study period, the most common regimens were platinum-based chemotherapy with or without ICI in first and second line, and median rwOS was 13.2 and 8.2 months, respectively. These results indicate the need for more effective targeted therapies in this patient population.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 24","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70272","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70272","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Targeted therapies have been shown to improve outcomes in metastatic non-small cell lung cancer (mNSCLC) with driver mutations. We evaluated the real-world prevalence of human epidermal growth factor receptor 2 (HER2; ERBB2) tumor gene mutations among patients with mNSCLC and described historical treatments and outcomes in patients with HER2-mutant mNSCLC, during a period when there was no approved targeted therapy for HER2-mutant mNSCLC.

Materials and Methods

This retrospective observational study used a US nationwide de-identified NSCLC clinico-genomic database. Eligible patients were adults diagnosed with HER2-mutant mNSCLC from January 2014 to July 2021 without co-occuring epidermal growth factor receptor (EGFR) tumor mutations. Descriptive statistics were used to summarize prevalence, baseline characteristics and treatment patterns. Clinical outcomes were estimated with Kaplan–Meier analyses.

Results

Among 9206 patients with mNSCLC, 164 (1.78%) met the eligibility criteria (mean age: 67.3 years, 63.4% White, 56.7% female, and 53.0% with a smoking history). 132/164 (80.5%) had at least one line of treatment. Platinum-based chemotherapy (45.5%) and immune checkpoint inhibitor (ICI) with chemotherapy (28.0%) were the most frequently used first-line treatments. The median (95% confidence interval [CI]) real-world (rw) progression-free survival in first-line was 5.5 (4.8, 6.2) months and 3.0 (2.3, 4.2) months in second-line. The median rw overall survival in first-line was 13.2 (10.6, 18.4) months and 8.2 (6.6, 13.2) months in second-line.

Conclusion

During this study period, the most common regimens were platinum-based chemotherapy with or without ICI in first and second line, and median rwOS was 13.2 and 8.2 months, respectively. These results indicate the need for more effective targeted therapies in this patient population.

Abstract Image

查看原文本刊更多论文

来自美国临床基因组数据库的HER2 （ERBB2）突变转移性非小细胞肺癌患者的真实世界患病率、治疗模式和结果

目的：靶向治疗已被证明可以改善转移性非小细胞肺癌（mNSCLC）的预后。我们评估了人类表皮生长因子受体2 (HER2；ERBB2)肿瘤基因突变在mNSCLC患者中发生，并描述了her2突变mNSCLC患者的历史治疗和结果，在her2突变mNSCLC没有获批靶向治疗的时期。材料和方法：这项回顾性观察性研究使用了美国全国范围内的非小细胞肺癌临床基因组数据库。符合条件的患者是2014年1月至2021年7月诊断为her2突变型小细胞肺癌的成年人，没有共同发生表皮生长因子受体（EGFR）肿瘤突变。描述性统计用于总结患病率、基线特征和治疗模式。用Kaplan-Meier分析估计临床结果。结果：9206例小细胞肺癌患者中，164例（1.78%）符合入选标准（平均年龄67.3岁，白人63.4%，女性56.7%，有吸烟史53.0%）。132/164（80.5%）至少接受过一次治疗。以铂为基础的化疗（45.5%）和免疫检查点抑制剂（ICI）联合化疗（28.0%）是最常用的一线治疗方法。一线患者的真实无进展生存期（rw）中位数（95%置信区间[CI]）为5.5（4.8,6.2）个月，二线患者为3.0（2.3,4.2）个月。一线患者的中位总生存期为13.2（10.6,18.4）个月，二线患者为8.2（6.6,13.2）个月。结论：在本研究期间，一线和二线最常见的方案是铂基化疗伴或不伴ICI，中位rwOS分别为13.2和8.2个月。这些结果表明，在这一患者群体中需要更有效的靶向治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.